Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine by Giovanna Gentile et al.
RAPID COMMUNICATION
Genetic polymorphisms related to efficacy and overuse of triptans
in chronic migraine
Giovanna Gentile • Marina Borro • Noemi Lala •
Serena Missori • Maurizio Simmaco •
Paolo Martelletti
Received: 23 April 2010 / Accepted: 2 July 2010 / Published online: 22 July 2010
 Springer-Verlag 2010
Abstract Migraine is a common type of headache and its
most severe attacks are usually treated with triptans, the
efficacy of which is extremely variable. Several SNPs in
genes involved in metabolism and target mechanisms of
triptans have been described. To define an association
between genetic profile and triptan response, we classified
a migrainous population on the basis of triptan response
and characterized it for polymorphisms in the genes coding
for monoamine oxidase A, G protein b3 and the cyto-
chrome CYP1A2. Analysis of the association between
genotypic and allelic frequencies of the analyzed SNPs and
the grade of response to triptan administration showed a
significant correlation for MAOA uVNTR polymorphism.
Further stratification of patients in abuser and non-abuser
groups revealed a significant association with triptan
overuse and, within the abusers, with drug response to the
CYP1A2*1F variant.
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Introduction
Migraine is a common type of headache and its most severe
attacks are usually treated with triptans. The triptans are
mainly used for the acute treatment of migraine attacks and
their mechanism of action is based on the stimulation of
serotonin receptors, yet their therapeutic benefits are largely
variable among different subjects. Different metabolic rates
may probably account for different levels of drug response.
Enzymes responsible for triptan degradation are the
monoamine oxidase MAOA and the cytochrome P450: the
former for sumatriptan and rizatriptan and the latter for
eletriptan, frovatriptan and naratriptan. The two systems
cooperate in the metabolism of almotriptan (MAO A and
CYP3A4) and zolmitriptan (MAOA, CYP1A2 and
CYP3A4) [1]. Several SNPs in these genes are related to
alteration of enzymatic activity, and genotypization can
thus contribute to define a specific metabolic background
responsible for the drug’s efficacy.
Polymorphisms in genes involved in transduction signal
via the HT1B/1D receptor, as the C825T SNP in the gene
coding the G protein b3 subunit (GNB3), can also be
important determinants of triptan therapy outcome [2].
The aim of this work was to detect a correlation between
triptan response and individual genetic profile, character-
izing a panel of gene SNPs involved in the pharmacoki-
netics and pharmacodynamics of triptans in a chronic
migrainous population.
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Patients and methods
Description of analyzed populations
The study received the approval of the University Ethic
Committee. All patients signed a written consent before
enrollment in the study.
A total of 150 patients (26 males and 124 females)
affected with CM, aged 25–81 years, were enrolled in the
study. All patients were referred to the Regional Referral
Headache Centre of 2nd School of Medicine of Sapienza
University at Sant’Andrea Hospital in Rome. The diagnosis
of CM was performed according to the 2006 ICHD-II
revised rules [3]. The majority of patients (64.7%) were
administered a single type of triptan (12.7% sumatriptan,
19.4% eletriptan, 11.4% rizatriptan, 16.6% almotriptan, 4%
frovatriptan, 0.6% zolmitriptan), while the remaining sub-
jects (35.3%) were administered different triptans.
Headache frequency and drug overuse were evaluated
by means of headache diaries filled in for at least
3 months. The diagnosis of medication overuse headache
(MOH) was performed according to the 2006 ICDH-II
revised rules [4]. A total of 75 patients (16 males and 59
females) were triptan abusers, 51 were non-abusers and
24 patients were excluded because of the assignation to
mixed abuser class (triptans plus other class of acute
migraine drugs).
Acute therapy response was assessed by evaluating the
following end points: 2 and 24 h pain free or of pain relief
(relief [50% of the VAS at baseline) plus the presence or
not of recurrence. On this basis, the patients were catego-
rized as follows: 0–25% response (class 1); 25–50%
response (class 2); 50–75% response (class 3); 75–100%
response (class 4).
The distribution of response class and drug overuse in
the studied population is reported in Table 1.
Genetic analysis
Genomic DNA was isolated from peripheral blood using
the X-tractor Gene system (Corbett Life Science, Austra-
lia). We studied the following DNA polymorphisms: an
untranslated variable number of tandem repeats (uVNTR)
of 30 base pairs located about 1.1 kb upstream of the ATG
initiation codon of monoamine oxidase A (MAO A) gene;
a A [ C substitution at position -163 and a G [ A
transition at position -3860 in the 50 noncoding region of
the CYP1A2 gene, indicated as *1F allele (rs762551) and
*1C allele (rs2069514), respectively, and a C [ T transi-
tion at nucleotide 825 (rs5443) in the coding sequence of
GNB3 gene, which produces a truncated form of the
protein.
CYP1A2 and GNB3 polymorphisms were genotyped by
pyrosequencing technology (Pyrosequencer PyroMark ID
system—Biotage AB and Biosystems, Uppsala, Sweden),
while MAOA uVNTR was evaluated by microchannel
electrophoresis on chip (Bioanalyzer, Agilent technologies,
Santa Clara, CA, USA), according to the protocols
described in Gentile et al. [5].
Statistical analysis
Chi-square Hardy–Weinberg equilibrium (HWE) test cal-
culator for biallelic markers available at http://www.oege.
org/software/hwe-mr-calc.shtml [6] was used to test for
deviations of genotype frequencies from HWE.
Chi-square analysis was applied to detect associations
between the genotype/alleles and the therapy response
class and to compare genotypic and allelic frequencies
between abusers and non-abusers.
In the case of the X-linked MAOA uVNTR polymor-
phism, male patients (26 out of 150 total subjects) were
excluded from statistical analysis. Values of p \ 0.05 were
considered to be significant.
Results
All the polymorphisms analyzed in the total population
were in HWE.
Genotype distributions were calculated for GNB3 and
CYP1A2 in 150 migraineurs. In the case of the GNB3
C825T SNP, we found 68 (45.3%) homozygous noncarri-
ers of the mutated 825T allele, 63 (42%) heterozygous
carriers and 19 (12.7%) homozygous carriers of the
mutated 825T allele. The CYP1A2 *1C allele was found in
9 (6%) heterozygous and 1 (0.7%) homozygous carriers,
the remaining 140 (93.3%) subjects being homozygous
noncarriers of the mutated -3860A. The CYP1A2*1F
allele was present in 61 (40.7%) heterozygous carriers and
Table 1 Categorization of patients (n = 150) based on response
grade and drug overuse of triptans
Patients no.
Therapy response grade
0–25% (class 1) 38
25–50% (class 2) 29
50–75% (class 3) 35
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17 (11.3%) homozygous carriers of the mutated -163C
allele, whereas 72 (48%) subjects were homozygous non-
carriers of the mutated -163C allele. The MAOA uVNTR
polymorphism was detected in the female population
(n = 124) in the 3R, 4R and 5R variants, the 3R and 4R
alleles accounting for 98.3% of the total. Since the 5R
variant was detected only in 4 patients out 150, it was
excluded from statistical analysis.
Association between genotype and allelic frequencies of
the analyzed SNPs and the grade of response to triptan
administration in the total population was assessed by
Chi-square analysis.
A significant correlation was found only for MAOA
uVNTR polymorphism, as shown in Table 2. In particular,
compared to the expected values, we found an overrepre-
sentation of 4R/4R genotype and an underrepresentation of
the 3R/3R genotype in class 1 (0–25% response) and 3
(50–75%), whereas in class 2 (25–50%) and 4 (75–100%)
we detected an increased number of 3R/3R homozygotes
and a decreased number of 4R/4R homozygotes
(v2 = 18.4; df = 6; p = 0.005). Similar results were
obtained on analyzing allelic distribution: the number of
3R variant was decreased in class 1 and 3 and increased in
class 2 and 4, while the 4R variant was overrepresented in
class 1 and 3 and underrepresented in class 2 and 4
(v2 = 16.0; df = 3; p = 0.001).
The migrainous population was then stratified according
to drug overuse, and genotypic and allelic distributions
were compared in abusers and non-abusers. All the poly-
morphisms analyzed in the stratified population were in
HWE, except for CYP1A2*1C in the abuser group that
gives a p \ 0.05 (v2 = 7; df = 1) due to the presence of
the rare AA homozygote.
The frequencies of MAOA, GNB3 and CYP1A2*1C
variants were found not to be significantly different
between abuser and non-abuser groups. In contrast, we
found an increased number of -163C allele of CYP1A2 in
the non-abuser class and an overrepresentation of -163A
allele in the abuser group (v2 = 4.74; df = 1; p = 0.029),
as shown in Table 3. Hence, therapy response/genotype
association was separately assessed for abusers and non-
abusers. In the abuser group, a significant association with
response grade was found for CYP1A2*1F allele (Table 4).
In detail, A allele was overrepresented in the classes 1 and
2 and underrepresented in the classes 3 and 4 (v2 = 7.79;
df = 3; p = 0.05). In the non-abuser group, there was no
significant correlation of CYP1A2*1F allelic frequency
and therapy response.
Discussion
We present the results of a pilot study aimed to explore the
potentiality of pharmacogenomics to tailor CM therapy.
Polymorphisms in genes involved in metabolism (CYP450
and MAOA) and in target mechanisms (GNB3) of triptans
were genotyped in 150 chronic migraineurs to assess their
relation with the efficacy of triptans.
Among the considered gene SNPs, no relation between
genotype and/or allelic frequencies and response grade
of triptans was found, except for MAOA uVNTR
polymorphism.
Concerning the GNB3 gene, a previous study reported
an association between the C825T SNP and the response to
triptan in cluster headache (CH) [2]. This polymorphism
affects the signal transduction mechanism linked to
Table 2 Distribution of genotypic and allelic frequencies of MAOA uVNTR in the drug response classes assessed by Chi-test analysis
MAOA uVNTR genotypea Therapy response grade
0–25% (class 1) 25–50% (class 2) 50–75% (class 3) 75–100% (class 4)
Obs. Exp. Obs. Exp. Obs. Exp. Obs. Exp.
3R3R 0 3.60 8 3.33 1 3.87 7 5.2
3R4R 12 11.2 10 10.4 10 12.1 18 16.2
4R4R 15 12.2 7 11.2 18 13.1 14 17.6
MAOA uVNTR allelesb 0–25% (class 1) 25–50% (class 2) 50–75% (class 3) 75–100% (class 4)
Obs. Exp. Obs. Exp. Obs. Exp. Obs. Exp.
3R 13 18.7 26 17.0 12 20.1 32 27.2
4R 42 36.3 24 33.0 47 38.9 48 52.8
Statistical analysis was performed on 124 females. The 5R variant was excluded from statistical analysis
df degrees of freedom
a v2 = 18.4; df = 6; p = 0.005
b v2 = 16.0; df = 3; p = 0.001
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5-hydroxytryptamine (5-HT1B and 5-HT1D) receptors, the
common targets of triptans [7]. In chronic migraine, we
found no association of GNB3 C825T SNP with therapy
response. However, 98.3% of the population studied by
Schurks et al. was treated with sumatriptan, whereas our
migraine population was heterogeneous with respect to the
class of triptan medications. The discrepancy in the results
probably reflects the distinct clinical presentation of dif-
ferent headaches as CH and CM, as well as the multifac-
torial aspect of headache physiology and triptan
pharmacokinetics. On the other hand, in CM we found
some genotype–response correlation for MAOA uVNTR.
Monoamine oxidase A is the metabolic enzyme of
neurotransmitters, and uVNTR polymorphism, located in
the promoter region, affects its transcriptional activity
modulating the levels of monoamines. In detail, enzyme
expression is relatively high for carriers of 3.5 or 4 repeats
(MAO A-high) and lower for carriers of 2, 3 or 5 repeats
(MAO A-low) [8]. The 3R and 4R variants account for
about 98% of the population we studied, and analysis of
their frequencies in different response classes shows a
peculiar, bimodal distribution where the long allele (higher
enzymatic activity) is overrepresented in the classes 1–3
and underrepresented in classes 2–4. The 4R homozygous
genotype shows the same profile. Considering that high
MAOA activity should faster metabolize the triptans, the
increased number of 4R allele in class 1 may be expected,
as well as its underrepresentation in class 4. In contrast, the
4R frequency in classes 2 and 3 seems not to be consistent
with the hypothesis that extensive metabolizers show poor
therapy response, giving rise to the possibility of additional
interacting factors affecting the phenotype.
A more clear and interesting link between drug response
and genetic profile emerged stratifying patients in abuser
and non-abuser groups, in the case of the CYP1A2*1F. The
cytochrome P450 enzyme CYP1A2 plays a main role in
the metabolism of a variety of structurally unrelated
compounds, including a broad range of different drugs, and
its activity is widely modulated by a plethora of inducer/
inhibitor molecules. As the other members of the cyto-
chrome P450 superfamily, CYP1A2 gene is highly poly-
morphic and the *1F allele is associated with reduced
metabolic activity. In particular, -163C allele presents
reduced enzymatic activity compared to the -163A one,
which also shows enhanced inducibility by environmental
and chemical factors [9]. In relation to CYP1A2 pharma-
cokinetics, a higher enzymatic activity should determine
faster rate of drug degradation, thus lowering drug con-
centration below the therapeutic threshold. The higher
frequency of -163A allele in the abuser compared to non-
abuser group may be explained by a reduced availability
of the assumed triptan, leading to drug overuse. This
assumption is supported by the finding that inside the
abuser group, the higher activity allele -163A is also
associated with low grade of therapy response (class 1 and 2).
Hence, the -163A carriers, having a lower drug avail-
ability, attain limited therapeutic effect and overuse of
drug.
In conclusion, our data suggest that individual genetic
traits could in effect contribute to determine the treatment
outcome of triptans, which frequently prompts drug
misuse and overuse [10, 11]. However, the complexity of
CM pathophysiology, still poorly characterized, and the
incomplete definition of molecular pathways involved in
the action and kinetics of triptans make it difficult to rec-
ognize genetic determinants strong enough to achieve reli-
able prevision of the efficacy of therapy [12, 13]. Further,
reproducibility and validation of genetic association studies
in the research area of CM management strongly need
standardized and more accurate methods for unambiguous
Table 3 Distribution of allelic frequencies of CYP1A2 -163A [ C





Abusers (n = 75)
n (%)
Non-abusers (n = 51)
n (%)
Obs. Exp. Obs. Exp.
A 108 (72.0) 100 (66.6) 60 (58.9) 68 (66.6)
C 42 (28.0) 50 (33.4) 42 (41.2) 34 (33.4)
v2 = 4.74; df = 1; p = 0.029
df degrees of freedom




0–25% (class 1) 25–50% (class 2) 50–75% (class 3) 75–100% (class 4)
Obs. Exp. Obs. Exp. Obs. Exp. Obs. Exp.
A 29 27.4 25 20.2 15 18.7 39 41.8
C 9 10.6 3 7.84 11 7.28 19 16.2
v2 = 7.79; df = 1; p = 0.050
df degrees of freedom
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classification of therapy efficacy, till now based on patient
self-reports [14, 15].
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